DK1092431T3 - Lasofoxifenpræparater - Google Patents

Lasofoxifenpræparater

Info

Publication number: DK1092431T3
Authority: DK; Denmark
Prior art keywords: lasofoxifene; preparations; effect; potency; achieves
Prior art date: 1999-09-29

Application number

DK00308152T

Other languages

English (en)

Inventor

David Duane Thompson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-29

Filing date

2000-09-19

Publication date

2006-12-18

2000-09-19 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-12-18 Application granted granted Critical

2006-12-18 Publication of DK1092431T3 publication Critical patent/DK1092431T3/da

Links

GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title abstract 3
229960002367 lasofoxifene Drugs 0.000 title abstract 3
238000002360 preparation method Methods 0.000 title 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)

DK00308152T 1999-09-29 2000-09-19 Lasofoxifenpræparater DK1092431T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15665299P	1999-09-29	1999-09-29

Publications (1)

Publication Number	Publication Date
DK1092431T3 true DK1092431T3 (da)	2006-12-18

Family

ID=22560457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00308152T DK1092431T3 (da)	1999-09-29	2000-09-19	Lasofoxifenpræparater

Country Status (20)

Country	Link
US (1)	US6436977B1 (da)
EP (1)	EP1092431B1 (da)
JP (1)	JP2001097862A (da)
KR (1)	KR100468246B1 (da)
AT (1)	ATE339201T1 (da)
AU (1)	AU781828B2 (da)
CA (1)	CA2321369C (da)
CO (1)	CO5200833A1 (da)
CY (1)	CY1105235T1 (da)
DE (1)	DE60030654T2 (da)
DK (1)	DK1092431T3 (da)
ES (1)	ES2269071T3 (da)
HU (1)	HUP0003836A3 (da)
IL (1)	IL138634A (da)
MY (1)	MY121519A (da)
NZ (2)	NZ516413A (da)
PE (1)	PE20010680A1 (da)
PT (1)	PT1092431E (da)
TW (1)	TWI224001B (da)
ZA (1)	ZA200005141B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function
CN1610551A (zh)	2001-07-06	2005-04-27	恩德制药公司	用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
WO2008058287A1 (en) *	2006-11-10	2008-05-15	Syndax Pharmaceuticals, Inc.	COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US20100298270A1 (en) *	2007-07-23	2010-11-25	Syndax Pharmaceuticals, Inc.	Novel Compounds and Methods of Using Them
US20100267779A1 (en) *	2007-07-23	2010-10-21	Syndax Pharmaceuticals, Inc.	Novel Compounds and Methods of Using Them
US20090149511A1 (en) *	2007-10-30	2009-06-11	Syndax Pharmaceuticals, Inc.	Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) *	2007-11-19	2009-05-28	Syndax Pharmaceuticals, Inc.	Combinations of hdac inhibitors and proteasome inhibitors
US20110182888A1 (en) *	2008-04-08	2011-07-28	Peter Ordentlich	Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
US20180098963A1 (en)	2016-10-11	2018-04-12	Duke University	Lasofoxifene treatment of breast cancer
CN117771239A (zh)	2018-04-10	2024-03-29	杜克大学	乳腺癌的拉索昔芬治疗
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5296486A (en)	1991-09-24	1994-03-22	Boehringer Ingelheim Pharmaceuticals, Inc.	Leukotriene biosynthesis inhibitors
US5366965A (en) *	1993-01-29	1994-11-22	Boehringer Mannheim Gmbh	Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) *	1997-05-01	1998-11-04	Merck & Co Inc	Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (en)	1998-08-06	2000-06-07	Pfizer Products Inc.	Estrogen agonists/antagonists
EP1086692A3 (en)	1999-07-28	2003-07-09	Pfizer Products Inc.	Estrogen agonists and antagonists for multiple indications

2000
- 2000-09-06 US US09/656,273 patent/US6436977B1/en not_active Expired - Lifetime
- 2000-09-11 AU AU56618/00A patent/AU781828B2/en not_active Ceased
- 2000-09-19 AT AT00308152T patent/ATE339201T1/de not_active IP Right Cessation
- 2000-09-19 DK DK00308152T patent/DK1092431T3/da active
- 2000-09-19 EP EP00308152A patent/EP1092431B1/en not_active Expired - Lifetime
- 2000-09-19 ES ES00308152T patent/ES2269071T3/es not_active Expired - Lifetime
- 2000-09-19 PT PT00308152T patent/PT1092431E/pt unknown
- 2000-09-19 DE DE60030654T patent/DE60030654T2/de not_active Expired - Lifetime
- 2000-09-21 IL IL138634A patent/IL138634A/en not_active IP Right Cessation
- 2000-09-25 TW TW089119761A patent/TWI224001B/zh not_active IP Right Cessation
- 2000-09-26 PE PE2000001009A patent/PE20010680A1/es not_active Application Discontinuation
- 2000-09-26 KR KR10-2000-0056344A patent/KR100468246B1/ko not_active Expired - Fee Related
- 2000-09-26 MY MYPI20004477A patent/MY121519A/en unknown
- 2000-09-26 ZA ZA200005141A patent/ZA200005141B/xx unknown
- 2000-09-27 CA CA002321369A patent/CA2321369C/en not_active Expired - Fee Related
- 2000-09-28 NZ NZ51641300A patent/NZ516413A/xx unknown
- 2000-09-28 HU HU0003836A patent/HUP0003836A3/hu unknown
- 2000-09-28 NZ NZ50720000A patent/NZ507200A/xx unknown
- 2000-09-29 CO CO00074167A patent/CO5200833A1/es not_active Application Discontinuation
- 2000-09-29 JP JP2000297908A patent/JP2001097862A/ja active Pending
2006
- 2006-09-20 CY CY20061101350T patent/CY1105235T1/el unknown

Also Published As

Publication number	Publication date
ATE339201T1 (de)	2006-10-15
AU5661800A (en)	2001-04-05
EP1092431A3 (en)	2002-02-13
EP1092431A2 (en)	2001-04-18
DE60030654D1 (de)	2006-10-26
IL138634A0 (en)	2001-10-31
NZ516413A (en)	2004-12-24
KR100468246B1 (ko)	2005-01-27
PE20010680A1 (es)	2001-06-29
TWI224001B (en)	2004-11-21
NZ507200A (en)	2004-12-24
MY121519A (en)	2006-01-28
CA2321369C (en)	2007-07-17
ES2269071T3 (es)	2007-04-01
ZA200005141B (en)	2002-03-26
CA2321369A1 (en)	2001-03-29
PT1092431E (pt)	2006-12-29
KR20010061927A (ko)	2001-07-07
AU781828B2 (en)	2005-06-16
US6436977B1 (en)	2002-08-20
HUP0003836A3 (en)	2002-09-30
HU0003836D0 (en)	2000-12-28
HUP0003836A2 (hu)	2001-10-28
DE60030654T2 (de)	2007-04-05
IL138634A (en)	2006-08-01
CO5200833A1 (es)	2002-09-27
JP2001097862A (ja)	2001-04-10
CY1105235T1 (el)	2010-03-03
EP1092431B1 (en)	2006-09-13

Publication	Publication Date	Title
DK1157037T3 (da)	2003-11-24	GCSF-konjugater
EE200100594A (et)	2003-02-17	Uudsed ravimikompositsioonid, mis põhinevad antikolinergiliselt toimivatel ühenditel ja ß-mimeetikumidel
HN1999000066A (es)	1999-09-29	Formulaciones farmaceuticas
DE69931925D1 (de)	2006-07-27	2-chinolonen enthaltende arzneimittel
SE9802729D0 (sv)	1998-08-13	Novel Compounds
DK0971717T3 (da)	2002-03-25	Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
DK1092431T3 (da)	2006-12-18	Lasofoxifenpræparater
MXPA03003687A (es)	2003-08-07	Composiciones para cuidado dental.
BG106316A (en)	2002-08-30	Ambroxol-containing lozenge
AU1799800A (en)	2001-07-09	One-pack type post-foamable oxidation hair-dye compositions
FR2674755B1 (fr)	1995-02-03	Nouvelles compositions medicamenteuses immunostimulatrices.
MXPA02012015A (es)	2003-06-09	Ligandos de receptores para integrinas.
WO2001037780A8 (en)	2001-11-08	Urotensin-ii analogs
NO20021429D0 (no)	2002-03-21	1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
MXPA04005226A (es)	2004-10-11	1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
MXPA02003731A (es)	2003-12-11	Derivados novedosos de acido fusidico.
IL124344A0 (en)	1998-12-06	Novel dithiazoldioxides and the use thereof as microbicides
IL149749A0 (en)	2002-11-10	N-(1-phenylethyl)-5-phenylimidazole-2-amine compounds, their compositions and uses
ITRM920045A0 (it)	1992-01-21	Composizioni farmaceutiche ad attivita' anti-aging.
GB9921047D0 (en)	1999-11-10	Therapeutic antibody, immunogenic compositions & uses
AU2002233637A1 (en)	2002-09-24	Medicinal composition containing 1,3-thiazine derivative
ITMI961083A0 (it)	1996-05-29	Composizioni farmaceutiche orali contenenti chetotifene fumarato ad azione ritardo.
ITRM920044A1 (it)	1993-07-21	Composizioni farmaceutiche ad attivita' anti-aging.
ITRM920043A1 (it)	1993-07-21	Composizioni farmaceutiche ad attivita' anti-aging.